Actos (pioglitazone) is an oral diabetes medicine that prescribed to help control blood sugar levels for people with type 2 diabetes. Studies have shown a link between Actos usage and bladder cancer. Interim results from an American study found long-term Actos users had 40 percent more bladder cancers than people who never took the drug.
On June 15, 2011, the Food and Drug Administration took action and warned that patients taking Actos-containing medicines for more than 12 months and exposed to the largest doses over time may have a higher bladder cancer risk. Additionally, the FDA required new risk warnings on product inserts for Actos products.
The top Chicago lawyers at Meyers and Flowers are actively involved in the Actos litigation and have been named co-lead counsel for the consolidated Actos proceedings in Illinois state court.
For an update or questions regarding the pending Actos litigation, please contact our firm.